



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/817,950	03/27/2001	Paul M. Guyre	DC-0153	4097

26259 7590 03/11/2005

LICATLA & TYRRELL P.C.  
66 E. MAIN STREET  
MARLTON, NJ 08053

EXAMINER
----------

BELYAVSKIY, MICHAEL A

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED: 03/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

112

## Office Action Summary

Application No.

09/817,950

Applicant(s)

GUYRE ET AL.

Examiner

Michail A. Belyavskyi

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 04 January 2005.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-3 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-3 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

Art Unit: 1644

### DETAILED ACTION

1. Applicant's amendment, filed 01/04/05 is acknowledged.

Claims 1-3 are pending.

Claims 1-3 are under consideration in the instant application.

In view of the amendment filed 01/04/05, the following rejection remains:

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

*(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.*

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

3. Claims 1-3 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Coligan et al. (Current Protocols in Immunology, Greene Publishing Associates and Wiley-Interscience, New York, 1991; pages 2.1.1-2.1.3, 2.1.9-2.1.11, and 2.1.17-2.1.22) in view of U.S. Patent 5,077,216, Zwadlo et al (IDS Reference BA) and Zwadlo et al (IDS Reference AX) for the same reason set forth in the previous Office Action mailed on 10/05/04.

Applicant's arguments filed 01/04/05 have been fully considered but they are not persuasive.

Applicant asserts that : (i) none of the references teach that CD163 is useful for monitoring an early signaling event, i.e. within the first 1-12 hours in an inflammatory response cascade in a patient; (ii) Zwadlo et al. teaches away from the present invention in teaching that the RM3/1

Art Unit: 1644

antigen (i.e. CD163) is appearing in blood at 24 and 72 hours after exposure to the inflammatory stimulus, thus there is no motivation for the skilled artisan to modify the teaching in the art to monitor CD163 levels before 24 hours after exposure to the inflammatory stimulus, (iii) Arondel et al. teaching that early signaling events in an inflammatory response cascade can not be extrapolated by measuring protein levels at 0 and at 24 hr or later.

Contrary to Applicant's it is noted that it appears that applicant and the examiner differ on interpretation of the prior art. It is the Examiner's position that Zwaldo et al. (IDS Reference BA) teach that RM3/1 antigen (i.e. CD161 antigen) is useful for monitoring an early signaling event in an inflammatory response in a patient. The examiner disagree with Applicant interpretation that Zwaldo et al. teaches away from the present invention in teaching that the RM3/1 antigen (i.e. CD163) is appearing late in the inflammatory response. Zwaldo et al. teach that the levels of RM3/1 antigen (i.e. CD163) reached a maximum levels late in the inflammatory response. However, Applicants attention is drawn to pages 299, 301 and 303, wherein Zwaldo et al. explicitly teach that depending on the stage of inflammation RM3/1 antigen is expressed at different levels. Zwaldo et al. explicitly teaches that in acute inflammation, i.e. early in an inflammatory response, RM3/1 antigen expressed to varying degree, depending on the stage of inflammation. In addition, Zwaldo et al., (IDS Reference AX) teach to monitor the appearance of RM3/1 positive macrophages in blood between 24 and 72 hr post inflammatory response (see abstract in particular). It would be immediately obvious to one skill in the art that Zwaldo et al., teaches that detection of the expression of RM3/1, i.e. CD163 is useful for monitoring an early signaling event in an inflammatory response.

Moreover, the examiner disagreed with Applicant's interpretation of Arondel et al. reference. There is no teaching in said references that early signaling events in an inflammatory response cascade can not be extrapolated by measuring protein levels at 0 and at 24 hr or later. Arondel et al. monitor the balance of the expression levels between two different signals, i.e. inductive and inhibitory signals of inflammation. Arondel et al., teach that in addition to higher expression of IL1, M90T also caused a decrease in expression of IL-1ra, at 4 hr after infection, that at 8 hr p.i. was caught up probably due to massive recruitment of producing cells in infected zone, thereby restoring IL-1/IL-1ra balance. However, it is noted that Arondel et al., teaching is irrelevant for the instant application, since the instant claims do not recite measuring the ration between inductive and inhibitory signals.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to use the MAC2-158 or MAC2-48 antibodies as capture antibodies taught by the '216 patent and the antibodies taught by Zwaldo et al. as the detection antibody in the ELISA assay taught by Coligan et al. to have a method for monitoring the course of an inflammatory condition or inflammatory response in a patient by detecting the levels of CD163 in the biological sample as taught by Zwaldo.

One of ordinary skill in the art would have been motivated to use the antibodies taught by the '216 patent and Zwaldo et al. in the ELISA taught by Coligan et al. because to detect and

Art Unit: 1644

monitor the presence of CD163 in a biological sample, such as human plasma, during an early inflammatory condition/process, such as rheumatoid arthritis by detecting CD163 (i.e. RM3/1 antigen) as taught by Zwaldo et al.

One of ordinary skill in the art at the time the invention was made would have been motivated to do so, because detecting CD163 levels can be used to monitor an early inflammatory response cascade in the patient, as taught by Zwaldo et al. CD163 levels in biological sample can be detected using the antibodies taught by the '216 patent and Zwaldo et al. in the ELISA taught by Coligan et al.

From the combined teaching of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

4. No claim is allowed.

**THIS ACTION IS MADE FINAL.** See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.


5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskiy whose telephone number is 571/272-0840. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571/272-0841.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michail Belyavskyi, Ph.D.  
Patent Examiner  
Technology Center 1600  
March 3, 2005

  
CHRISTINA CHAN  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600